Dolor is one of the five classical signs of inflammation (along with rubor, calor, tumor, functio laesa), representing the pain sensation that arises from tissue damage and the subsequent inflammatory response. Mediated by an "inflammatory soup" of prostaglandins, bradykinin, cytokines, and other algesic substances, dolor serves a protective function by limiting movement of injured tissue, preventing further damage, and signaling the need for rest during the healing process. While acute dolor is adaptive and self-limiting, chronic dolor beyond normal healing timelines (>3 months) suggests failed resolution of inflammation or central sensitization.
Imagine a construction site where a critical water pipe has burst. Dolor is the alarm system that immediately activates: flashing red lights, sirens blaring, automated messages telling workers to evacuate the area. The alarm isn't the problem itself—it's the protective warning that prevents workers from entering a dangerous zone and causing more damage while repairs are underway.
Now imagine that alarm has multiple volume controls. The initial break triggers local sensors (nociceptors) that detect the leak. Then, chemical crews arrive (prostaglandins, bradykinin, cytokines) and they don't just fix the pipe—they also turn up the alarm sensitivity. What used to require a major leak to trigger the alarm now responds to a drip. This is peripheral sensitization: the threshold for the alarm drops so even minor disturbances set it off.
Normally, once repairs are complete, the chemical crews leave, the alarm resets, and work resumes. But if the repair fails or the alarm system itself becomes faulty, the sirens keep blaring even after the pipe is fixed. Now the alarm is no longer protecting the site—it's preventing normal operations. This is chronic dolor: pain that has outlived its protective purpose, transforming from guardian to saboteur.
Dolor arises from a precisely orchestrated molecular cascade triggered by tissue damage. The sequence involves multiple parallel pathways that converge on nociceptor activation:
Primary inflammatory mediators:
- Tissue damage → cell membrane phospholipids release arachidonic acid
- Arachidonic acid → COX-2 enzyme → PGE2 (prostaglandin E2)
- PGE2 binds EP receptors on nociceptor terminals → ↑ cAMP via PKA → sensitizes voltage-gated sodium channels (Nav1.7, Nav1.8)
- Simultaneously: Arachidonic acid → 5-LOX → Leukotriene B4 (LTB4) → amplifies nociceptor sensitivity
Kinins and neuropeptides:
- Tissue damage → activates plasma kallikrein → cleaves high-molecular-weight kininogen → releases bradykinin
- Bradykinin binds B2 receptors on nociceptors → activates phospholipase A2 → further arachidonic acid release (positive feedback loop)
- Substance P released from nociceptor terminals → binds NK1 receptors → mast cell degranulation → histamine and serotonin release
- This creates "neurogenic inflammation": the pain system amplifies its own signal
Cytokine contribution:
- IL-1β, IL-6, TNF-α released by macrophages and damaged cells
- These cytokines bind receptors on nociceptor terminals and dorsal root ganglion cell bodies
- IL-1β → NF-kB activation in sensory neurons → upregulates Nav1.8 channel expression (days-long sensitization)
- TNF-α → p38 MAPK pathway → phosphorylates TRPV1 channels → lowers activation threshold from 43°C to 37°C (now activated by body temperature)
Peripheral to central transition:
- Sustained nociceptor input → glutamate release in dorsal horn of spinal cord
- Glutamate → NMDA receptor activation → Ca²⁺ influx into second-order neurons
- Ca²⁺ → PKC activation → phosphorylates NMDA and AMPA receptors → enhanced synaptic transmission
- microglial activation in spinal cord → release of BDNF → further NMDA receptor upregulation
- This establishes central sensitization: the spinal cord becomes hyperexcitable, maintaining pain even after peripheral inflammation resolves
graph TD
A[Tissue Damage] --> B[Membrane Phospholipids]
B --> C[Arachidonic Acid Release]
C --> D[COX-2 Pathway]
C --> E[5-LOX Pathway]
D --> F[PGE2]
E --> G[LTB4]
F --> H[Nociceptor Sensitization]
G --> H
A --> I[Bradykinin Release]
I --> J[B2 Receptor Activation]
J --> H
J --> K[More Arachidonic Acid]
K --> C
A --> L[Cytokine Release]
L --> M["IL-1β, IL-6, TNF-α"]
M --> N[Nociceptor Receptors]
N --> H
H --> O[Sustained Nociceptor Firing]
O --> P[Spinal Dorsal Horn]
P --> Q["Glutamate → NMDA Activation"]
Q --> R["Ca²⁺ Influx"]
R --> S[PKC Activation]
S --> T[Central Sensitization]
P --> U[Microglial Activation]
U --> V[BDNF Release]
V --> T
Resolution phase (normal healing):
- Lipid mediator class switching: COX-2 is acetylated by aspirin or S-nitrosylated endogenously
- Acetylated COX-2 produces Aspirin-triggered resolvins from DHA/EPA
- Resolvins (RvD1, RvD2, RvE1), maresins, protectins bind ALX-FPR2 and other GPCRs on nociceptors
- These SPMs do NOT block pain initially—they resolve inflammation while allowing protective dolor
- As inflammation resolves → inflammatory mediators clear → nociceptor threshold returns to baseline
- Timeline: acute inflammatory pain should resolve within days to weeks (tissue-dependent)
Understanding dolor through a cPNI lens reveals why conventional pain management often fails and how to intervene more effectively.
Patient populations:
- Acute inflammation patients (post-surgical, trauma, wound healing): Dolor is adaptive and necessary. The challenge is managing it without impairing healing.
- Chronic pain patients (fibromyalgia, osteoarthritis, low back pain): Dolor has transitioned from protective to pathological. The inflammatory soup may have cleared, but central sensitization persists.
- Autoimmune conditions (rheumatoid arthritis, inflammatory bowel disease): Ongoing inflammation maintains peripheral sensitization, but central mechanisms often dominate the clinical picture.
- Post-infection syndromes (Long COVID, post-Lyme): Failed inflammatory resolution → persistent low-grade inflammation → sustained dolor despite pathogen clearance.
Connection to metamodels:
- Metamodel 3 (Psycho-Neuro-Immunology): Dolor is where all three systems converge. Psychological stress via cortisol and noradrenaline modulates nociceptor sensitivity. Chronic stress → glucocorticoid resistance → cytokines remain elevated → sustained dolor.
- Metamodel 5 (Evolutionary Mismatch): Modern environments create "sterile inflammation" without true pathogen threat. Chronic low-grade inflammation from processed foods, sedentarism, and sleep deprivation maintains a baseline inflammatory soup, lowering the threshold for dolor.
- Selfish Immune System: From the immune system's perspective, dolor is a resource allocation signal—"invest energy in repair here, avoid using this tissue." When the immune system becomes selfish (autoimmune conditions), it maintains dolor to monopolize metabolic resources.
Clinical thresholds and biomarkers:
- PGE2 levels: Normal tissue <50 pg/mL; inflamed tissue 200-1000 pg/mL. Levels >1000 pg/mL indicate severe inflammation.
- IL-6: Acute inflammation 10-100 pg/mL; chronic low-grade inflammation 2-10 pg/mL. Even subtle elevations (>3 pg/mL) can sensitize nociceptors over weeks to months.
- Quantitative sensory testing: Thermal pain threshold normally ~43°C. Peripheral sensitization lowers to 37-40°C. Central sensitization shows temporal summation (repeated identical stimuli feel progressively worse).
- Timeline criterion: Acute dolor should peak 24-72 hours post-injury and resolve within 7-21 days (tissue-dependent). Pain persisting >3 months suggests transition to chronic pain.
Intervention implications:
-
Acute phase (days 0-7): NSAIDs can be used judiciously but recognize they impair COX-2-mediated wound healing. Better alternatives: topical heat therapy (increases local blood flow, clears metabolites), gentle movement within tolerance (mechanotransduction promotes resolution), omega-3 supplementation (provides substrate for SPMs).
-
Subacute phase (weeks 1-12): Focus on resolution promotion rather than suppression. SPMs (RvD1, RvE1) clinically available as supplements. Curcumin and Boswellia modulate inflammatory mediators without blocking protective prostaglandins. Address gut dysbiosis and intestinal permeability—40% of chronic pain patients have elevated LPS driving systemic inflammation.
-
Chronic phase (>3 months): Peripheral inflammation is often minimal; central sensitization dominates. Pain neuroscience education to reconceptualize dolor. Graded motor imagery and mirror therapy to retrain cortical pain maps. Address microglial activation with minocycline (off-label) or natural microglia modulators (palmitoylethanolamide, alpha-lipoic acid). Restore autonomic balance—chronic pain is marked by sympathetic dominance; vagus nerve stimulation or breathwork can shift toward parasympathetic.
-
Cross-system interventions: Chronic dolor often reflects failed communication between immune, nervous, and endocrine systems. Restore circadian rhythm (inflammation peaks at night if circadian disrupted). Optimize vitamin D (modulates both TLR4 signaling and nociceptor sensitivity). Address insulin resistance—hyperinsulinemia upregulates inflammatory pathways and sensitizes nociceptors.
Common clinical pitfalls:
- Treating chronic dolor as if it were acute inflammation (NSAIDs for months/years)
- Ignoring central sensitization—pursuing endless imaging for "structural causes" when the nervous system is the problem
- Suppressing all inflammation without supporting resolution (blocking COX-2 without providing SPM substrates)
- Missing the gut-brain axis contribution—SIBO, dysbiosis, and leaky gut perpetuate systemic inflammation that maintains dolor
- Dolor is one of five classical inflammation signs described by Celsus (30 BC-38 AD); functio laesa added by Galen
- Primary algesic mediators: PGE2 (most potent), bradykinin (fastest onset, <1 minute), Substance P (longest duration)
- PGE2 does not directly activate nociceptors—it sensitizes them so other stimuli (heat, pressure, pH) become painful at lower thresholds
- Bradykinin is the most potent pain-inducing substance known (10-100x more potent than PGE2 in direct activation)
- TNF-α can lower TRPV1 activation threshold from 43°C to 37°C—body temperature becomes painful
- Transition from acute to chronic pain occurs in ~20% of patients with acute inflammatory pain; risk factors include high initial pain intensity, catastrophizing, and pre-existing anxiety/depression
- NSAIDs reduce dolor by 30-50% but delay wound healing by 20-40% depending on tissue type (bone healing most affected)
- Aspirin-triggered resolvins are 10,000x more potent than aspirin at resolving inflammation on a per-molecule basis
- Central sensitization can develop within 48-72 hours of sustained nociceptor input—early aggressive treatment prevents chronification
- Microglial activation in chronic dolor persists for months after peripheral inflammation resolves, maintaining central sensitization
- Heat therapy (40-45°C) increases local blood flow by 200-300%, accelerating clearance of inflammatory mediators
- Omega-3 index (EPA+DHA as % of total RBC fatty acids) <4% associated with impaired SPM production and prolonged inflammatory pain; optimal >8%
- inflammation — dolor is the pain component of the inflammatory response, one of five cardinal signs
- rubor — redness from vasodilation that occurs simultaneously with dolor; both mediated by prostaglandins
- calor — heat sensation accompanying dolor; both from increased local metabolic activity and blood flow
- tumor — swelling that physically distorts tissues, contributing to dolor via mechanical nociceptor activation
- functio laesa — loss of function that dolor enforces by making movement painful; protective immobilization
- nociceptors — primary sensory neurons activated by inflammatory mediators to generate dolor signals
- PGE2 — most important prostaglandin sensitizing nociceptors and generating dolor; COX-2 product
- bradykinin — rapidly acting kinin that directly activates B2 receptors on nociceptors, producing intense dolor
- Substance P — neuropeptide released by nociceptors that amplifies dolor via neurogenic inflammation and mast cell activation
- mast cells — release histamine, serotonin, and tryptase contributing to inflammatory soup and dolor
- IL-1β — pro-inflammatory cytokine that sensitizes pain pathways via NF-κB upregulation of Nav1.8 channels
- IL-6 — dual role cytokine; acutely sensitizes nociceptors, chronically promotes resolution if TNF-α is cleared
- TNF-α — lowers TRPV1 threshold via p38 MAPK, making normal body temperature painful; key chronic dolor driver
- NSAIDs — reduce dolor by inhibiting COX-2 and PGE2 synthesis but impair resolution and wound healing
- COX-2 — inducible enzyme producing PGE2 and other prostaglandins; acetylation by aspirin switches to SPM production
- peripheral sensitization — lowered nociceptor threshold caused by inflammatory mediators; dolor becomes easier to trigger
- central sensitization — spinal cord and brain hyperexcitability from sustained nociceptor input; dolor persists after inflammation resolves
- wound healing — dolor protects tissue during repair by enforcing rest; excessive dolor suppression impairs healing
- chronic pain — dolor that persists beyond normal healing timeframe (>3 months); often independent of ongoing inflammation
- resolvins — specialized pro-resolving mediators that clear inflammation while preserving protective dolor during healing
- heat therapy — increases blood flow and inflammatory mediator clearance, reducing dolor without suppressing protective inflammation
- arachidonic acid — precursor to both pro-inflammatory eicosanoids (PGE2, LTB4) and resolution lipid mediators
- 5-LOX — produces leukotrienes from arachidonic acid; LTB4 amplifies nociceptor sensitization
- glutamate — primary excitatory neurotransmitter released by nociceptors in spinal cord; drives central sensitization
- NMDA receptor — ionotropic glutamate receptor; activation required for transition from acute to chronic dolor
- BDNF — brain-derived neurotrophic factor released by microglia; upregulates NMDA receptors and maintains central sensitization
- microglial activation — spinal cord immune cells that transition from protective to pathological in chronic dolor
- autonomic nervous system — sympathetic dominance lowers pain threshold; parasympathetic activation raises it
- cortisol — glucocorticoid that should resolve inflammation; in chronic stress, cortisol resistance maintains inflammatory mediators
- glucocorticoid resistance — impaired cortisol signaling in chronic stress; cytokines remain elevated, sustaining dolor
- SPMs — specialized pro-resolving mediators (resolvins, maresins, protectins) that actively terminate inflammation and restore normal pain thresholds
- omega-3 fatty acids — EPA and DHA are substrates for SPM synthesis; deficiency impairs inflammatory resolution and prolongs dolor
- gut dysbiosis — altered microbiome composition increases systemic LPS and pro-inflammatory cytokines, lowering pain thresholds system-wide
- LPS — lipopolysaccharide from gram-negative bacteria; activates TLR4 → NF-κB → cytokine production → sensitizes nociceptors
- circadian rhythm — inflammatory mediator production peaks during sleep; circadian disruption causes inappropriate cytokine timing and chronic dolor
- insulin resistance — hyperinsulinemia upregulates inflammatory pathways and increases nociceptor sensitivity via multiple mechanisms